{
    "2020-06-19": [
        [
            {
                "time": "2023-10-10",
                "original_text": "Full results from EMPERIAL exercise ability trials presented",
                "features": {
                    "keywords": [
                        "EMPERIAL",
                        "exercise",
                        "ability",
                        "trials",
                        "presented"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-10",
                "original_text": "The Zacks Analyst Blog Highlights: Eli Lilly & Company, AstraZeneca, AbbVie and Bristol-Myers Squibb",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst",
                        "Blog",
                        "Eli Lilly",
                        "AstraZeneca",
                        "AbbVie",
                        "Bristol-Myers Squibb"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-10",
                "original_text": "Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Stock",
                        "Roundup",
                        "FDA",
                        "Approvals",
                        "MRK",
                        "LLY",
                        "NVS",
                        "GSK"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}